Physician profile
Simon Blanc
NPI 1255683652
$160,227.87
in general payments reported to CMS, 2019-2025
66 companies · $47K in 2025
The $47K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $46K · 2021: $59.84 · 2022: $21.97 · 2023: $4,369 · 2024: $1,691 · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Consulting Fee: $12K · Food and Beverage: $5,537 · Travel and Lodging: $3,600 · Long Term Medical Supply Or Device Loan: $1,196 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,658.60 |
| Consulting Fee | $12,136.50 |
| Food and Beverage | $5,536.53 |
| Travel and Lodging | $3,599.72 |
| Long Term Medical Supply Or Device Loan | $1,196.40 |
| Education | $215.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $42,561.52 | 2019-2025 | Rybrevant, Talvey, Darzalex |
| Celgene Corporation | $27,207.87 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $19,209.59 | 2024-2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $16,998.78 | 2019-2025 | Datroway, Enhertu, Tagrisso |
| Daiichi Sankyo INC. | $16,406.60 | 2019-2025 | Datroway, Enhertu |
| Array Biopharma INC | $6,955.83 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Emd Serono, INC. | $6,503.09 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $6,082.32 | 2019-2025 | Onivyde, Somatuline Depot |
| Genzyme Corporation | $4,333.05 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $3,426.55 | 2019-2025 | |
| Sobi, INC | $3,318.47 | 2024-2025 | |
| Heron Therapeutics, INC. | $1,622.47 | 2019 | |
| Pfizer INC. | $701.76 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $494.77 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| E.R. Squibb & Sons, L.L.C. | $445.07 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Blanc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.